{"id":458417,"date":"2021-03-16T07:33:10","date_gmt":"2021-03-16T11:33:10","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=458417"},"modified":"2021-03-16T07:33:10","modified_gmt":"2021-03-16T11:33:10","slug":"wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\/","title":{"rendered":"WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101"},"content":{"rendered":"

\nEngages Investor Relations Firm to Drive Awareness
\n<\/h2>\n
\n

VANCOUVER, British Columbia, March 16, 2021 (GLOBE NEWSWIRE) — WPD Pharmaceuticals Inc. (\u201cWPD\u201d or the \u201cCompany\u201d) (CSE: WBIO) (FSE: 8SV1), <\/strong>a clinical stage pharmaceutical company, is pleased to announce that it has engaged Paediatric Oncology expert, Prof. David Walker to support and develop preclinical and clinical programs for WPD101 in glioblastoma.<\/p>\n

Prof. Walker has over 40 years of medical experience in Paediatric Oncology and is a world-renowned expert in brain cancer. Throughout his career, Prof. Walker has led a number of brain tumor clinical trials and co-chaired the International Consortium of Childhood Low Grade Glioma 1997 – 2014. He co-chaired the Royal College of Paediatrics and Child Health (RCPCH), Society of British Neurological Surgeons (SBNS) and Royal College of Nursing (RCN) working party to establish a network of children\u2019s brain tumour treatment centres across the UK reporting in 1997. He helped to develop the Children\u2019s Brain Tumour Research Centre at the University of Nottingham.<\/p>\n

Since retiring from clinical practice, Prof. Walker continues to work in research at the University of Nottingham and at the Harley Street Children\u2019s Hospital and medico-legal practice. Currently, he is an Emeritus Professor of Paediatric Oncology, Children\u2019s Brain Tumour Research Centre, at the University of Nottingham. His current research program seeks to develop methods for minimizing risk of cerebellar mutism syndrome, saving sight due to visual pathway glioma and chairing the recently launched Children\u2019s Brain Tumour Drug Delivery Research Consortium to enhance awareness of CNS directed drug delivery as a priority for drug development.<\/p>\n

Prof. Walker will be advising WPD with strategic decisions related to the development of WPD101 in glioblastoma. He will provide expertise and advise on preclinical studies necessary to move product to the clinical stage and to develop First in Human (FIM) protocols in adults and in children.<\/p>\n

\n Mariusz Olejniczak, CEO <\/strong>of WPD comments, \u201cWe are thrilled to have the support and scientific expertise of Dr. David Walker as we continue progressing on our clinical trials for WP101 in the UK and Europe. He is an expert in his field, and his experience and deep-rooted knowledge of paediatric oncology will be invaluable as we further our studies and make important decisions to create the best possible outcomes, efficiencies and effectiveness of these trials.\u201d<\/em><\/p>\n

\n Prof. David Walker <\/strong>comments, \u201cI have been involved in initiating the children\u2019s brain tumour drug delivery consortium (www.cbtddc.org) as a research initiative to raise awareness of the opportunities for optimising drug delivery for the treatment of children\u2019s brain tumours. This initiative has attracted significant clinical, academic and commercial interest as a strategy for children\u2019s brain tumours with overlapping technical opportunities in adult neuro oncology practice.\u00a0 Low-grade glioma are a developmental abnormality in children\u2019s brains accounting for 40% of all brain tumours in this age group. The molecular changes are increasingly being clarified and tested as drug targets.\u00a0High grade glioma in children have significant overlap with the same tumours in adulthood but also significant differences, \u00a0anatomically and biologically. Current treatments are relatively ineffective and have high risk of brain damage linked to the use of radiation. Investigating novel drug delivery methods offers an opportunity to enhance the efficacy and reduce brain damaging toxicity.\u00a0WPD Pharmaceuticals has appreciated the opportunities for optimising drug delivery as a strategy in this group of brain diseases across all ages.\u201d<\/em><\/p>\n

WPD also announces that it has engaged Arrowhead Business and Investment Decisions, LLC., (\u201cArrowhead<\/strong>\u201d) to provide investor relations support and brand awareness within the investment community. The Company has agreed to pay Arrowhead US$20,000 for a three month term, with the option to extend for another three month term at the same fixed cost. Arrowhead will not receive any securities of the Company as compensation for their services.<\/p>\n

\n About WPD Pharmaceuticals <\/strong>\n <\/p>\n

WPD is a biotechnology research and development company with a focus on oncology and virology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has licensed in certain countries 10 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at medical institutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.<\/p>\n

WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things. The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes for most compounds 30 countries in Europe and Asia, including Russia.<\/p>\n

\n On Behalf of the Board<\/strong>\n <\/p>\n

\n \u2018Mariusz <\/em>
\n Olejniczak\u2019<\/em>
\n
\u00a0Mariusz Olejniczak
CEO, WPD Pharmaceuticals<\/p>\n

\n Contact<\/strong>\n <\/p>\n

Investor Relations
Email: investors@wpdpharmaceuticals.com
Tel: 604-428-7050
Web: www.wpdpharmaceuticals.com\u00a0<\/p>\n

Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.<\/em><\/p>\n

\n This press release contains forward-looking statements. Forward-looking statements are statements that contemplate activities, events or developments that the Company can develop effective drugs against cancer and possibly viruses<\/em>
\n .<\/em>
\n Factors which may prevent the forward looking statement from being realized include that our supply of compounds for testing may not be sufficient for our needs; lack or funds, permits, subcontractors or other factors may delay our plans; competitors or others may successfully challenge a granted patent and the patent could be rendered void; we may be unable to raise sufficient funding for our research; we may be unable to expend sufficient funds on research to keep our sublicense rights; our grant applications may not be successful or if successful, we may not meet the requirements to receive the grants awarded; that our drugs don\u2019t provide positive treatment, or if they do, the side effects are damaging; and competitors may develop better or cheaper drugs; our plans may be delayed; we may not be able to get commercial quantities of our drugs made; and we may be unable to obtain regulatory approval for any drugs we develop. Readers should refer to the risk disclosure included from time-to-time in the documents the Company files on SEDAR, available at www.sedar.com. Although the Company believes that the assumptions inherent in these forward-looking statements are reasonable, they are not guarantees of future performance and, accordingly, they should not be relied upon and there can be no assurance that any of them will prove to be accurate. Finally, these forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update them except as required by applicable law.<\/em>\n <\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Engages Investor Relations Firm to Drive Awareness VANCOUVER, British Columbia, March 16, 2021 (GLOBE NEWSWIRE) — WPD Pharmaceuticals Inc. (\u201cWPD\u201d or the \u201cCompany\u201d) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, is pleased to announce that it has engaged Paediatric Oncology expert, Prof. David Walker to support and develop preclinical and clinical programs for WPD101 in glioblastoma. Prof. Walker has over 40 years of medical experience in Paediatric Oncology and is a world-renowned expert in brain cancer. Throughout his career, Prof. Walker has led a number of brain tumor clinical trials and co-chaired the International Consortium of Childhood Low Grade Glioma 1997 – 2014. He co-chaired the Royal College of Paediatrics and Child Health (RCPCH), Society of British Neurological … <\/p>\n

Continue reading “WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-458417","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nWPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Engages Investor Relations Firm to Drive Awareness VANCOUVER, British Columbia, March 16, 2021 (GLOBE NEWSWIRE) — WPD Pharmaceuticals Inc. (\u201cWPD\u201d or the \u201cCompany\u201d) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, is pleased to announce that it has engaged Paediatric Oncology expert, Prof. David Walker to support and develop preclinical and clinical programs for WPD101 in glioblastoma. Prof. Walker has over 40 years of medical experience in Paediatric Oncology and is a world-renowned expert in brain cancer. Throughout his career, Prof. Walker has led a number of brain tumor clinical trials and co-chaired the International Consortium of Childhood Low Grade Glioma 1997 – 2014. He co-chaired the Royal College of Paediatrics and Child Health (RCPCH), Society of British Neurological … Continue reading "WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-16T11:33:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDY5MCM0MDY1NDUxIzIxOTQwNTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101\",\"datePublished\":\"2021-03-16T11:33:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\\\/\"},\"wordCount\":1112,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDY5MCM0MDY1NDUxIzIxOTQwNTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\\\/\",\"name\":\"WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDY5MCM0MDY1NDUxIzIxOTQwNTM=\",\"datePublished\":\"2021-03-16T11:33:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDY5MCM0MDY1NDUxIzIxOTQwNTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDY5MCM0MDY1NDUxIzIxOTQwNTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\/","og_locale":"en_US","og_type":"article","og_title":"WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101 - Market Newsdesk","og_description":"Engages Investor Relations Firm to Drive Awareness VANCOUVER, British Columbia, March 16, 2021 (GLOBE NEWSWIRE) — WPD Pharmaceuticals Inc. (\u201cWPD\u201d or the \u201cCompany\u201d) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, is pleased to announce that it has engaged Paediatric Oncology expert, Prof. David Walker to support and develop preclinical and clinical programs for WPD101 in glioblastoma. Prof. Walker has over 40 years of medical experience in Paediatric Oncology and is a world-renowned expert in brain cancer. Throughout his career, Prof. Walker has led a number of brain tumor clinical trials and co-chaired the International Consortium of Childhood Low Grade Glioma 1997 – 2014. He co-chaired the Royal College of Paediatrics and Child Health (RCPCH), Society of British Neurological … Continue reading \"WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-16T11:33:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDY5MCM0MDY1NDUxIzIxOTQwNTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101","datePublished":"2021-03-16T11:33:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\/"},"wordCount":1112,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDY5MCM0MDY1NDUxIzIxOTQwNTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\/","name":"WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDY5MCM0MDY1NDUxIzIxOTQwNTM=","datePublished":"2021-03-16T11:33:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDY5MCM0MDY1NDUxIzIxOTQwNTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDY5MCM0MDY1NDUxIzIxOTQwNTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wpd-pharmaceuticals-engages-world-renowned-paediatric-oncology-expert-to-support-glioblastoma-programs-for-wpd101\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=458417"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458417\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=458417"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=458417"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=458417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}